SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Koc, S. Articles by Martin, P. J. Search for Related Content PubMed PubMed Citation Articles by Koc, S. Articles by Martin, P. J. Related Collections Neoplasia Transplantation Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 December 2000, Vol. 96, No. 12, pp. 3995-3996 BRIEF REPORT Thalidomide for treatment of patients with chronic graft-versus-host disease Sibel Koc, Wendy Leisenring, Mary E. D. Flowers, Claudio Anasetti, H. Joachim Deeg, Richard A. Nash, Jean E. Sanders, Robert P. Witherspoon, Frederick R. Appelbaum, Rainer Storb, and Paul J. Martin From the Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, and Department of Medicine, University of Washington, Seattle, WA. In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD). All patients had thrombocytopenia or cGVHD that evolved directly from acute GVHD as an indicator of a poor prognosis. The study drug (thalidomide or placebo) was administered initially at a dose of 200 mg orally per day, followed by a gradual increase to 800 mg/d if side effects were tolerable. Treatment with the study drug was discontinued before resolution of cGVHD in 23 (92%) of the 25 patients who received thalidomide and in 17 (65%) of the 26 patients who received placebo (P = .02). Neutropenia and neurologic symptoms were the most frequent reasons for early discontinuation of treatment with thalidomide. The duration of treatment with thalidomide was too short to assess its efficacy in controlling cGVHD. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. C. Vigorito, P. V. Campregher, B. E. Storer, P. A. Carpenter, C. K. Moravec, H.-P. Kiem, M. L. Fero, E. H. Warren, S. J. Lee, F. R. Appelbaum, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD Blood, July 16, 2009; 114(3): 702 - 708. [Abstract] [Full Text] [PDF] S. J. Lee and M. E. D. Flowers Recognizing and Managing Chronic Graft-Versus-Host Disease Hematology, January 1, 2008; 2008(1): 134 - 141. [Abstract] [Full Text] [PDF] C. Cutler, D. Miklos, H. T. Kim, N. Treister, S.-B. Woo, D. Bienfang, L. B. Klickstein, J. Levin, K. Miller, C. Reynolds, et al. Rituximab for steroid-refractory chronic graft-versus-host disease Blood, July 15, 2006; 108(2): 756 - 762. [Abstract] [Full Text] [PDF] P.-K. Li, B. Pandit, D. L. Sackett, Z. Hu, J. Zink, J. Zhi, D. Freeman, R. W. Robey, K. Werbovetz, A. Lewis, et al. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol. Cancer Ther., February 1, 2006; 5(2): 450 - 456. [Abstract] [Full Text] [PDF] B. L. Stewart, B. Storer, J. Storek, H. J. Deeg, R. Storb, J. A. Hansen, F. R. Appelbaum, P. A. Carpenter, J. E. Sanders, H.-P. Kiem, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease Blood, December 1, 2004; 104(12): 3501 - 3506. [Abstract] [Full Text] [PDF] D. G. Maloney, B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru Non-Myeloablative Transplantation Hematology, January 1, 2002; 2002(1): 392 - 421. [Abstract] [Full Text]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020